Technology | ECG | October 08, 2015

CardioSecur 22-Lead Mobile ECG Enables 360-Degree View of the Heart

Device with mobile application allows 10,000 minutes of ECG recording per 1GB via smartphone or tablet

CardioSecur mobile ECG, 22-lead, 360 degree view of the heart, CardioSecur Pro

Image courtesy of CardioSecur

October 8, 2015 — Personal MedSystems introduced the first and only 22-lead mobile electrocardiogram (ECG) system, CardioSecur, at the European Society of Cardiology Congress 2015, Aug. 29-Sept. 2 in London. The next generation of ECG solutions can be run with a smartphone or tablet PC, four electrodes and the CardioSecur App enabling the diagnosis and localization of cardiac ischemia, rhythm disorders and posterior wall infarctions. Clinical-grade quality readings allow a 360-degree view of the heart and therefore new diagnostic possibilities. CardioSecur's technology has been validated in several clinical studies and is available in two versions: CardioSecur Pro for professional use and CardioSecur Active for home use by patients.

The conventional 12-lead ECG has surely proven its worth in the diagnosis of cardiac disease. Nevertheless the display possibilities of a 12-lead ECG are limited to only 65 degrees in the transverse plane. This might be one of the reasons up to half of people who suffer from angina or silent ischemia, have normal ECG readings. In Europe alone, coronary artery disease still accounts for 4 million deaths every year. Symptoms for myocardial infarction are often indistinct while about one out of three heart attacks occurs symptom-free, which makes precise diagnosis even more difficult. Next to modern therapy options the need for enhanced diagnosis tools supporting physicians is crucial.

Quality and accuracy of CardioSecur has been validated in a clinical study against standard-of-care 10-electrode, 12-lead ECG systems and shows 99.5 percent accuracy. Using only four electrodes mitigates artifacts to a bare minimum, ensuring maximum signal quality and stable lead depiction. As the four electrodes are placed on very marked positions of the thorax, lead misplacement, often consequential to highly divers anatomies, is eradicated.

The professional 22-lead version CardioSecur Pro enables use in house calls, bed-ridden or reduced mobility patients as well as emergency situations. The lightweight 50g cable is accompanied by the Pro app which allows 10,000 minutes of ECG recording per 1GB via smartphone or tablet PC. The full ECG report can be sent directly to electronic patient records or colleagues and can be air printed. An automatic interpretation function is also available.

For more information: www.cardiosecur.com

Related Content

U.S. Soldiers Have Worse Heart Health Than Civilians
News | Cardiac Diagnostics | June 06, 2019
Active duty Army personnel have worse cardiovascular health compared to people of similar ages in the civilian...
Late Dinner and No Breakfast Worsens Outcomes After Heart Attack
News | Cardiac Diagnostics | May 23, 2019
People who skip breakfast and eat dinner near bedtime have worse outcomes after a heart attack, according to research...
HRS Releases New Expert Consensus Statement on Arrhythmogenic Cardiomyopathy
News | Cardiac Diagnostics | May 14, 2019
The Heart Rhythm Society (HRS) released a first-of-its-kind consensus statement with guidance on the evaluation and...
New Best Practices Help Manage Heart Attack Patients Without Significant Signs
News | Cardiac Diagnostics | April 15, 2019
For the first time in the United States, doctors with the American Heart Association (AHA) have outlined best practices...
The most recent U.S. Food and Drug Administration (FDA) clearance was Siemens Healthineers high-sensitivity troponin I assays (TnIH) for the Atellica IM and ADVIA Centaur XP/XPT in vitro diagnostic analyzers. The test helps in the early diagnosis of myocardial infarctions without the need for serial tropic testing. The time to first results is 10 minutes.

The most recent U.S. Food and Drug Administration (FDA) clearance was Siemens Healthineers high-sensitivity troponin I assays (TnIH) for the Atellica IM and ADVIA Centaur XP/XPT in vitro diagnostic analyzers. The test helps in the early diagnosis of myocardial infarctions without the need for serial tropic testing. The time to first results is 10 minutes. 

Feature | Cardiac Diagnostics | March 22, 2019 | Linda C. Rogers, Ph.D.
Troponins are a family of proteins found in skeletal and heart (cardiac) muscle fibers that produce muscular contract
ACC/AHA Update Guidance for Preventing Heart Disease; Stroke
Feature | Cardiac Diagnostics | March 18, 2019
The choices we make every day can have a lasting effect on our heart and vascular health. Adopting a heart healthy...
AHA Statement Warns Hookah Smoking May Harm the Heart
News | Cardiac Diagnostics | March 08, 2019
Smoking tobacco in waterpipes, more commonly known as hookahs, results in inhaling toxic chemicals, often at levels...
PTSD Alone Does Not Increase Heart Disease Risk in Veterans
News | Cardiac Diagnostics | February 20, 2019
February 20, 2019 — Post-traumatic stress disorder (PTSD) by itself does not explain the...
Hormone Therapy May Increase Cardiovascular Risk During Gender Transition
News | Cardiac Diagnostics | February 18, 2019
Patients receiving hormone therapy as part of their gender-transition treatment had an elevated risk for cardiovascular...
Overlay Init